|Bid||1,610.00 x 0|
|Ask||1,670.00 x 0|
|Day's Range||1,642.00 - 1,662.00|
|52 Week Range||1,408.80 - 1,749.40|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||18.67|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||0.76 (4.62%)|
|1y Target Est||1,644.50|
With the change of leadership for GSK's pharmaceutical business, the Triangle won't necessarily be losing its GSK leader.
Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.
GlaxoSmithKline plc (LON:GSK) is about to trade ex-dividend in the next 2 days. You can purchase shares before the 8th...
Under the terms of the agreement, GSK will own 68% of the consumer health joint venture and Pifzer will own the remaining 32%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 1) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Odonate ...
Moody's Investors Service ("Moody's") placed the A1 senior unsecured long-term rating of Pfizer Inc. ("Pfizer") under review for downgrade. At the same time, Moody's affirmed Pfizer's Prime-1 commercial paper rating.
Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.
(Bloomberg Opinion) -- The merger of Pfizer Inc.'s off-patent drug business with struggling specialty drugmaker Mylan Inc., announced early Monday morning, should come as a relief for investors on both sides of the transaction. Analysts have been clamoring for Pfizer to split off its Upjohn division focused on legacy drugs from its core prescription-drug operations so the drug giant could sharpen its focus on the higher-margin innovative business. This deal is a chance for CEO Albert Bourla to finally make the separation. And while Mylan holders may look back wistfully at Teva Pharmaceuticals Industry Ltd.’s $40 billion buyout offer in 2015 – this merger doesn’t offer the same type of immediate return – the deal with Pfizer gives them a 43% stake in a stronger company and will free Mylan’s assets from a management team that has had a calamitous recent run.Pfizer’s slim-down started with the highly successful spinoff of its animal health unit in 2013 and continued in December when it formed a consumer joint venture with GlaxoSmithKline PLC. The company should reap benefits from completing its journey. In its pre-deal form, Pfizer risked years of sluggish growth from declining sales of older drugs. Separating those products will flatter the revenue growth of the company’s newer medicines, and could have the same effect on its valuation. Pfizer is raising $12 billion in debt that the new company will carry, and keeping the cash. The deal will strengthen Pfizer’s balance sheet and help the company further bolster its roster of novel treatments. The Mylan combination is an excellent way to help Upjohn succeed on its own, and could boost the return on a split Pfizer would likely have pursued anyway. The specialty and generic drug business is brutally competitive, and pricing pressure in the U.S. has squashed profitability for the entire sector. That’s one reason Mylan comes so cheap: The company was worth $25 billion just last year but had a market cap below $10 billion before Monday's announcement. Scale will help the new business push back on pricing, and its broad lineup of products and geographic reach will also help it stand out. The combined company will be less levered than stand-alone Mylan and is expected to generate more than $4 billion in annual free cash flow. All of that makes a strong case in favor of this deal for Mylan investors. The most significant point in its favor, however, might be the planned departure of CEO Heather Bresch, who will retire when the deal closes. She has played a starring role alongside pricing pressure in shrinking the company’s valuation, to the point where Mylan felt compelled to consider its strategic options.Her tenure has brought price-fixing investigations, congressional inquiries into price increases for life-saving EpiPens, delays for crucial products, and repeated earnings misses. She further tarnished Mylan's reputation by investing in coal to lower its tax bill while simultaneously developing asthma medication, collecting rich paychecks as its share price plunged, and enacting shareholder-unfriendly corporate governance.A leadership change should help the market refocus on the good parts of the company, including a valuable international business. Pfizer veteran Michael Goettler will pilot the new company. It would be hard for him to be anything but an improvement. The deal removes a strategic cloud over Pfizer and a management miasma from Mylan. Investors are likely to enjoy the better weather. To contact the author of this story: Max Nisen at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
(Bloomberg) -- Drugmakers AstraZeneca Plc and Roche Holding AG joined major European rivals in raising their estimates for full-year results as new medicines begin to pay off.Sales and core earnings per share at Switzerland’s Roche will rise by a percentage in the mid- to high-single digits this year, the company said, as new drugs for cancer and multiple sclerosis offset pressure on older products. At Astra, product sales for the year are now expected to increase by a low double-digit percentage, helped by demand for the U.K. drugmaker’s roster of new cancer treatments. The stock surged in London trading.Like Astra and Swiss rival Novartis AG, Roche is seeing a handful of new medicines take over as the blockbusters that buoyed sales for a decade fade. Sales of Roche’s hemophilia therapy Hemlibra and Tecentriq for cancer breezed past analysts’ estimates in the first half. Astra’s cancer franchise saw sales surge by 51% last quarter amid demand for newcomers Lynparza and Imfinzi.GlaxoSmithKline Plc lifted its earnings forecast for the year on Wednesday, helped by a new shot for shingles that has quickly become a blockbuster. Glaxo is starting to encroach on Roche and Novartis’s turf by expanding into the cancer field. Novartis last week said earnings excluding some items would grow by a low double-digit to mid-teens percentage this year, the second boost to its estimate since the start of the year.Astra in ChinaRoche had previously nudged its estimate in April, saying it expected mid single-digit growth. The stock rose as much as 1.6% in Zurich trading. Glaxo gained as much as 1.9% in London, and Astra climbed as much as 6.5%, reaching a record.Astra’s second-quarter profit came in at 73 cents a share, well above analysts’ expectations, while net operating cash flow rebounded for the first half. The company remains open to acquisitions where it can add value, like its deal with Daiichi Sankyo Co. earlier this year for rights to a breast cancer drug, Chief Executive Officer Pascal Soriot said in an interview with Bloomberg TV.Sales in China, one of the company’s most important markets, rose 34%. Soriot had said earlier this year that performance there would be hurt in the second half by the country’s bulk-buying drug program for major cities.“The impact of those price pressures hasn’t been really coming as quickly as we thought initially, but they are coming,” he said in the interview.What Bloomberg Intelligence Says“We continue to see Astra as the preeminent large-pharma growth story.”\-- Sam Fazeli, pharma analystClick here to read the pieceRoche said its planned acquisition of Spark Therapeutics should close this year as it works with U.S. and U.K. regulators, but didn’t provide an explanation for the holdup.CEO Severin Schwan said the competition for Roche’s aging blockbuster cancer drugs will likely intensify in the fourth quarter. Rivals Amgen Inc. and Allergan Plc last week announced the availability of two cheaper biosimilar versions of Roche’s Avastin and Herceptin.In terms of stock performance, Novartis is ahead so far this year with a 23% gain. Glaxo has gained about 11% in the period, beating Roche’s and Astra’s 8% increases.(Updates with Astra CEO’s comments in sixth paragraph.)To contact the reporters on this story: Tim Loh in Munich at firstname.lastname@example.org;John Lauerman in London at email@example.comTo contact the editors responsible for this story: Eric Pfanner at firstname.lastname@example.org, Marthe Fourcade, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Drugmakers GlaxoSmithKline and Alexion Pharmaceuticals topped sales and adjusted earnings estimates Wednesday, though Alexion stock slipped as one rare-disease drug cannibalized another.
GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated. Shares of the FTSE-100 member initially rose as much as 2.5% to touch more than a two-year high of 1,701.6 as Walmsley outlined "another standout quarter" for the Shingrix vaccine, with sales more than doubling. "For at least the second quarter running, pharmaceutical sales were driven by the performance of the Shingrix vaccine in the U.S.," Andy Smith, analyst at Edison Investment research, said.
The results bode well for Chief Executive Officer Emma Walmsley's plans to rejuvenate GSK, which has included the spin off or sale of a number of businesses since she took over in 2017 and began focusing on the company's pharmaceuticals business. The new forecast reflects improved operating performance, lower interest expense and tax benefits, the company said. Shares of the FTSE-100 member initially rose as much as 2.5% to touch more than a two-year high of 1,701.6 as Walmsley outlined "another standout quarter" for the Shingrix vaccine, with sales more than doubling.
GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine. Shares of the FTSE-100 member were up 2% at 1,698 pence as Chief Executive Officer Emma Walmsley outlined "another standout quarter" for the vaccine, with sales more than doubling. The quarter bode well for Walmsley's plans to rejuvenate GSK's operations, which has included the spin off or sale of a number of units since she took over in 2017 to focus on the company's core pharmaceuticals business.